Trial
NCT00170950
Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Novartis
Collaborators
—
Condition
Hypertension
Intervention
Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1
Why stopped
The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-10-24